If you have been reading about drug affinity complex and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
. The first isotopes of transplutonium elements, americium-241 and curium-242, were synthesized in 1944 by Glenn T. Seaborg, Ralph A. James and Albert Ghiorso. Curium-242 was obtained by bombarding plutonium-239 with 32-MeV α-particles:
==== Experimental analogues ==== Insulin tregopil is an experimental ultra-fast-acting insulin that is being developed by Biocon. Unlike other insulin analogues, it is designed to be taken orally. It has been modified with the covalent attachment of a methoxy-triethylene-glycol-propionyl moiety at Lys-β29-amino group of the B-chain. This modification, along with the use of sodium caprate as a permeation enhancer, allows insulin tregopil to be absorbed through the gastrointestinal tract. Another oral analogue called ORMD-0801 is, as of 2025, in development by Oramed Pharmaceuticals. Insulin efsitora alfa is an experimental insulin analogue developed by Eli Lilly for the treatment of diabetes. Its glycemic control and safety were found to be similar to insulin degludec in a phase II clinical trial. NNC2215 is a bioengineered glucose-sensitive insulin analogue developed by Novo Nordisk researchers. The drug is designed to adjust its activity based on blood glucose levels, reducing insulin sensitivity when glucose concentrations are low, thereby lowering the risk of hypoglycemia. It also provides more stable blood sugar control by responding dynamically to fluctuations in glucose levels. A study on NNC2215 was published in the journal Nature on 16 October 2024, describing its potential as a major advancement in diabetes treatment and the role of protein engineering in future medicine. The development of glucose-sensitive insulin has been an area of interest in diabetes research since 1979, aiming to address blood sugar fluctuations.
The US Institute of Medicine (IOM) updated Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for B vitamins in 1998. At that time, there was not sufficient information to establish EARs and RDAs for pantothenic acid. In instances such as this, the Board sets Adequate Intakes (AIs), with the understanding that at some later date, AIs may be replaced by more exact information. The current AI for teens and adults ages 14 and up is 5 mg/day. This was based in part on the observation that for a typical diet, urinary excretion was approximately 2.6 mg/day, and that bioavailability of food-bound pantothenic acid was roughly 50%. AI for pregnancy is 6 mg/day. AI for lactation is 7 mg/day. For infants up to 12 months, the AI is 1.8 mg/day. For children ages 1–13 years, the AI increases with age from 2 to 4 mg/day. Collectively the EARs, RDAs, AIs and ULs are referred to as Dietary Reference Intakes (DRIs).
=== Fuselage === Circular-section structure of frames and stringers with a continuous main deck and lower decks fore and aft of the centre section. Rectangular windows in most interframe bays, eight ICAO Type 1a passenger doors on the main deck and three more on the lower deck portside; two freight hold doors and a galley supply door on the lower deck starboard. The main deck houses the flightdeck, two wardrobes, eight toilets, two pantries and a three-section passenger cabin. The lower deck houses three entry vestibules/luggage stores with hydraulic boarding stairs to ground level and fixed stairs to the main deck, a midships galley linked with the main deck by an electric lift, two freight holds (fore and aft of the passenger facilities), an avionics bay and two technical bays. The entire accommodation is pressurised and air-conditioned with "earphones for music or on-board cinema."
Sources: en.wikipedia.org
=== COVID-19 pandemic === In June 2020, following Novak Djokovic's Adria Tour, several players tested positive for COVID-19. Due to his possible exposure, Zverev announced on Twitter that he would be following self-isolation procedures after testing negative for the virus. However, one week later, Zverev was captured on video at a party in Monaco, prompting criticism from fellow tennis players Nick Kyrgios and Katie Boulter.
Skoropadskyi himself supported the idea of reviving the Cossack class in Ukraine as a privileged social group personally loyal to the hetman. However, his initiative was viewed with skepticism by his ministers, and the law on re-establishment of Cossack administration in Ukraine was adopted only in October 1918, shortly before the hetman's resignation, and never realized. - During Skoropadskyi's tenure in power the Ukrainian State developed diplomatic ties with Cossack entities in the Kuban and Don region.
Rubredoxin is an electron-carrier found in sulfur-metabolizing bacteria and archaea. The active site contains an iron ion coordinated by the sulfur atoms of four cysteine residues forming an almost regular tetrahedron. Rubredoxins perform one-electron transfer processes. The oxidation state of the iron atom changes between the +2 and +3 states. In both oxidation states the metal is high spin, which helps to minimize structural changes.
== Preparation of azide == The aforementioned conversion to acyl azide has been carried out multifariously; Bergmann utilized methyl ester and hydrazide, whereas more recent attempts have designed methods such as: nitrosylation of N-formylaminoacyl hydrazide and subsequent substitution by sodium azide, reaction of a carboxylic acid with diphenyl phosphorazidate, triethylamine, and a hydroxyl component, and reaction between TMS azide and the anhydride of an amino acid.
Proteoglycans are proteins that are heavily glycosylated. The basic proteoglycan unit consists of a "core protein" with one or more covalently attached glycosaminoglycan (GAG) chain(s). The point of attachment is a serine (Ser) residue to which the glycosaminoglycan is joined through a tetrasaccharide bridge (e.g. chondroitin sulfate-GlcA-Gal-Gal-Xyl-PROTEIN). The Ser residue is generally in the sequence -Ser-Gly-X-Gly- (where X can be any amino acid residue but proline), although not every protein with this sequence has an attached glycosaminoglycan. The chains are long, linear carbohydrate polymers that are negatively charged under physiological conditions due to the occurrence of sulfate and uronic acid groups. Proteoglycans occur in connective tissue.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.